

Proj. Ref. No. BAC4-21-033-A

End-User Property and Supply Division

Project SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (AMPULES/VIALS) FOR CY 2022
(FRAMEWORK AGREEMENT)

Opening of Bids: **11 January 2022**

ITEM NO.	QTY	UNIT	ITEM DESCRIPTION	ABC PER UNIT (PHP)	QUOTATIONS (all taxes included)	
					in figures	in words
1	32,560	Pc.	Atracurium besilate 10mg/mL, 2.5mL ampule (IV)	228.00		
2	16,750	Pc.	Atropine sulfate 1mg/mL, 1 mL ampul (IM, IV, SC)	26.50		
3	2,800	Pc.	Aztreonam 1g powder for injection (IV, IV Infusion)	4,888.88		
4	504	Pc.	Beractant 25 mg/ml suspension, 8mL Intratracheal administration vial	19,572.92		
5	204	Pc.	Beractant 25 mg/mL suspension, 4 mL Intratracheal administration vial	11,070.25		
6	12,840	Pc.	Bupivacaine Hydrochloride 0.5% 4 mL ampul (spinal) with 8% dextrose	350.00		
7	16,100	Pc.	Calcium folinate (leucovorin Ca) 10mg/mL, 5mL ampule/vial (IM, IV)	195.00		
8	3,830	Pc.	Cefotaxime sodium 500 mg vial + 2 mL diluent (IM, IV)	737.44		
9	63,900	Pc.	Cefuroxime sodium 750mg vial (IM, IV)	90.00		
10	6,101	Pc.	Cytarabine 100 mg/mL solution for injection, 1 mL	125.00		
11	2,660	Pc.	Deferoxamine mesilate powder, 500 mg vial (IM, IV infusion, SC)	343.95		
12	985	Pc.	Digoxin 250 micrograms/mL, 2 mL ampul (IM, IV)	210.00		
13	5,897	Pc.	Dobutamine Hydrochloride 50mg/mL, 5ml ampule (IV infusion)	390.00		
14	2,558	Pc.	Enoxaparin sodium 100mg/mL, 0.2mL pre-filled syringe (SC)	422.60		
15	6,000	Pc.	Ephedrine sulfate 50 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	91.50		
16	15,432	Pc.	Epoetin alfa (recombinant human erythropoietin) 4000 IU/0.4 mL, pre-filled syringe (IV, SC)	550.00		
17	300	Pc.	Epoetin Beta (recombinant erythropoietin) 2000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	530.00		
18	1,076	Pc.	Epoetin beta (recombinant erythropoietin) 5000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	1,278.98		

Proj. Ref. No. BAC4-21-033-A

End-User Property and Supply Division

Opening of Bids: **11 January 2022**Project SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (AMPULES/VIALS) FOR CY 2022
(FRAMEWORK AGREEMENT)

19	4,320	Pc.	Fluorescein (as sodium salt) 10% (100mg/mL), 5 mL ampul (IV)	575.00		
20	130	Pc.	Fondaparinux sodium 2.5 mg/0.5 mL solution (IV, SC)	1,389.15		
21	52	Pc.	Ganciclovir sodium 500 mg vial (IV infusion)	1,826.47		
22	15	Pc.	Goserelin acetate 10.8mg depot solution pre-filled syringe (SC)	14,077.89		
23	15	Pc.	Goserelin acetate 3.6mg depot solution, pre-filled syringe (SC)	4,118.80		
24	70	Pc.	Human recombinant tissue type plasminogen activator (alteplase) 50 mg powder for I.V. infusion	30,536.02		
25	1,716	Pc.	Insulin, regular(recombinant DNA human) 100 IU/mL, 10mL vial (SC, IV/IM)	470.00		
26	2,323	Pc.	Insulin, Biphasic Isophane Human 70/30 (recombinant DNA) 70% isophane suspension + 30% soluble insulin in 100 IU/mL, 10 mL vial (SC)	623.40		
27	2,314	Pc.	Isophane Insulin Human (recombinant DNA) 100 IU/mL, 10 mL vial (SC)	350.00		
28	1,770	Pc.	Isosorbide dinitrate 1mg/ml, 10mL ampule (IV)	792.00		
29	780	Pc.	Ketamine hydrochloride 50 mg/mL, 10 mL vial (IM, IV) (With PDEA Permit)	1,399.88		
30	36	Pc.	Leuporeline (as acetate) powder, 3.75mg single dose with syringe (IM, SC)	5,000.00		
31	3,200	Pc.	Levetiracetam 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial	2,348.00		
32	4,810	Pc.	Levobupivacaine 5 mg/mL solution for injection, 10 mL ampule (Epidural/local infiltration)	210.00		
33	85,474	Pc.	Lidocaine Hydrochloride 2%, 5mL ampule/vial (IM/IV)	36.63		
34	15,382	Pc.	Lidocaine Hydrochloride 2%, 50mL ampule/vial (IM, IV)	55.00		
35	1,805	Pc.	Lidocaine Hydrochloride 2%, 1.8 mL carpule (with epinephrine) (local infiltration)	29.00		
36	440	Pc.	Linezolid 2 mg/mL (600 mg/300 mL), solution for infusion (IV)	3,820.00		
37	15,485	Pc.	Magnesium sulfate heptahydrate 250mg/mL, 20mL vial (IV)	52.00		

Proj. Ref. No. BAC4-21-033-A

End-User Property and Supply Division

Opening of Bids: **11 January 2022**Project SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (AMPULES/VIALS) FOR CY 2022
(FRAMEWORK AGREEMENT)

38	8,170	Pc.	Methotrexate 25 mg/mL, 2 mL ampul/vial (IM, IV, Intrathecal) (as base)	199.00		
39	210	Pc.	Methotrexate sodium 100mg/mL, 10mL vial (IM, IV, Intrathecal) (preservative free)	7,500.00		
40	1,250	Pc.	Methylprednisolone 40 mg in single dose vial, solution for injection (IV, IM) (as sodium succinate)	668.90		
41	2,989	Pc.	Methylprednisolone lyophilized powder, 500 mg vial (IM, IV) (as sodium succinate)	1,256.00		
42	24,009	Pc.	Metronidazole 5 mg/mL, 100 mL vial (IV infusion)	57.00		
43	9,050	Pc.	Morphine Sulfate 10 mg/mL, 1 mL ampul (IM, IV, SC) or 16 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	79.50		
44	4,600	Pc.	Nalbuphine Hydrochloride 10 mg/mL, 1 mL ampul (IM, IV, SC) (With PDEA Permit)	103.00		
45	2,435	Pc.	Naloxone hydrochloride 400 micrograms/mL, 1 mL ampul (IM, IV, SC)	338.04		
46	5,000	Pc.	Paclitaxel 6mg/mL, 5mL vial (IV, IV infusion) (with special IV line)	995.00		
47	5,000	Pc.	Paclitaxel 6mg/mL, 16.7mL vial or 17mL vial (IV, IV infusion) (with special IV line)	1,957.00		
48	3,000	Pc.	Paclitaxel 6mg/mL, 25mL vial (IV, IV infusion) (with special IV line)	5,880.00		
49	3,000	Pc.	Paclitaxel 6mg/mL, 43.4mL vial (IV, IV infusion) (with special IV line)	5,100.00		
50	10,350	Pc.	Paracetamol 10 mg/mL, 50 mL vial solution for infusion (IV)	263.38		
51	16,160	Pc.	Paracetamol 10 mg/mL, 100 mL vial solution for infusion (IV)	318.98		
52	4,920	Pc.	Phenylephrine hydrochloride 10mg/1mL vial (With Compassionate Special Permit) (IV/IV Infusion)	628.00		
53	370	Pc.	Phenytoin sodium 50mg/mL, 2mL ampule (IV)	680.00		
54	26,720	Pc.	Piperacillin + Tazobactam (as sodium salt) 2 g piperacillin + 250 mg tazobactam per vial (IV infusion)	300.00		
55	55,228	Pc.	Piperacillin + Tazobactam (as sodium salt) 4 g piperacillin + 500 mg tazobactam per vial (IV infusion)	350.00		
56	14,382	Pc.	Potassium chloride 2meq/mL, 20mL vial (IV infusion)	48.00		

Proj. Ref. No. BAC4-21-033-A

End-User Property and Supply Division

Opening of Bids: **11 January 2022**Project SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (AMPULES/VIALS) FOR CY 2022
(FRAMEWORK AGREEMENT)

57	3,610	Pc.	Protamine sulfate 10mg/mL, 5mL ampule (IV) (With Compassionate Special Permit)	628.00		
58	1,800	Pc.	Remifentanyl 1mg lyophilized powder vial (IV Infusion) (With PDEA Permit)	1,500.00		
59	210	Pc.	Rituximab 10mg/mL, 50mL vial (IV)	43,859.52		
60	600	Pc.	Ropivacaine Hydrochloride 10mg/mL, 10mL ampule (IV)	442.00		
61	5,104	Pc.	Sodium bicarbonate 1mEq/mL, 50mL ampul/vial (adult) (IV infusion)	119.99		
62	1,110	Pc.	Sodium Bicarbonate 1 mEq/mL, 100 mL ampul/vial (adult) (IV infusion)	275.32		
63	29,760	Pc.	Sodium Chloride 2.5mEq/mL, 20mL vial	52.36		
64	125	Pc.	Somatostatin 250mcg ampule/vial (IV, IV infusion)	798.00		
65	510	Pc.	Somatostatin 3mg ampule/vial (IV, IV infusion)	5,598.00		
66	130	Pc.	Streptomycin sulfate 1 g vial (IM)	26.50		
67	112	Pc.	Valproic Acid 500 mg/ 5mL IV infusion, 5 mL vial	1,927.06		
68	630	Pc.	Verapamil Hydrochloride 2.5 mg/mL, 2 mL ampul (IV)	181.65		
69	2,510	Pc.	Vincristine sulfate 1 mg/mL, 1 mL vial (IV)	293.00		
70	2,540	Pc.	Vincristine sulfate 1 mg/mL, 2 mL vial (IV)	440.00		
71	120	Pc.	Vitamin B1 B6 B12 100 mg B1 + 100 mg B6 + 1 mg B12 per 3 Ml ampul (IV)	858.73		
72	330	Pc.	Voriconazole 200mg lyophilized powder for solution for IV infusion, 30mLVial	5,600.00		
TOTAL APPROVED BUDGET FOR THE CONTRACT: PhP213,818,572.05						

Approved by:


 Dean VICENTE Y. BELIZARIO, JR., M.D.
 Chairperson

(Signature over Printed Name of President/Gen. Manager)

(Name & Address of Company)

**TERMS & CONDITIONS FOR THE SUPPLY AND DELIVERY OF VARIOUS
DRUGS AND MEDICINES (AMPULES/VIALS) FOR CY 2022 (FRAMEWORK AGREEMENT)**
1 Indicate the **brand and packing of the item/s** offered.

Proj. Ref. No. BAC4-21-033-A

End-User Property and Supply Division

Project SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (AMPULES/VIALS) FOR CY 2022
(FRAMEWORK AGREEMENT)

Opening of Bids: 11 January 2022

- 2 The brand offered must be **at least five (5) years commercially available in the market from date of opening of bids.** Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).
- 3 **Submit the following documents, submission should be per product, with tab and per item number. Two (2) copies for the Valid Certificate of Product Registration and Certificate of Analysis (COA).**
 - a. **Memorandum of Agreement (MOA) and Certificate of exclusive/ authorized distributorship between the manufacturer and distributor.**

Distributors/suppliers must have certification from their principals that they are the exclusive distributor of the drug products authorized to submit tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in case of termination of distributorship agreement.
 - b. **Valid Certificate of Product Registration (CPR)** issued by the Food and Drug Administration (FDA).
 - **The name of the respective distributor should appear on the submitted CPR of the drug.**

Note: CPRs that will expire within three (3) months from the date of opening of bids should present the Official Receipt of renewal of application with the Document Tracking log for the CPR from the FDA.
 - c. **Certificate of Analysis (COA)** for the products offered (batch to be delivered if awarded) duly issued by an FDA accredited laboratory (local) and should contain information indicated in monograph of the drug. Sample analyzed must not be expired during the time of bidding. The result of assay submitted must be in the specific brand and should be in the exact dosage formulation of the drug being bidded. In cases where local laboratories are unavailable to perform drug assays, assays done abroad is accepted. The local COA is preferred and given more weight in the evaluation and awarding process.
 - d. **A notarized certificate** that it is the innovator drug (if applicable).
 - e. **Certificate of Good Manufacturing Process (CGMP).**
 - f. **Valid License to Operate (LTO).**
 - g. **A notarized certificate that the offered brand has not been subject to product complaint/product recall** for the past three (3) years.
 - h. **Certificate of Acceptance** from at least three (3) major hospitals issued within the year and should be supported with Sales Invoice (*for new item/brand offered only*).
 - i. **A notarized certificate** that there are sufficient stocks for the offered item/s for one (1) year.
- 4 The offered drug must conform to the latest Philippine Food and Drug Administration (FDA) Administrative Order **governing the generic labeling**

Proj. Ref. No. BAC4-21-033-A

End-User Property and Supply Division

Project SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (AMPULES/VIALS) FOR CY 2022
(FRAMEWORK AGREEMENT)

Opening of Bids: 11 January 2022

and packaging requirements.

4.1 For all tablets and capsules

4.1.1 **All tablets/capsules should be in foil or blister pack. A picture of the blister pack (front and back) should be submitted.**

4.1.2 Each individual flap in the tablet or capsule blister pack should be labeled with the generic name and brand.

4.1.3 Dosage form and strength of the Active Pharmaceutical Ingredients (API) should appear on each unit or every 2 units for products with multiple APIs.

4.1.4 Name of drug, lot or batch number and expiry date must appear on every standard blister pack/foil strip and on the container or inner packing. However, if the product is not restricted for dispensing in quantities less than the standard blister pack or foil strip, the batch or lot number and expiry date should appear on each unit.

4.1.5 Inner label must be the same as the outer label.

4.1.6 A complete drug literature/product insert must accompany the product.

5 The following must be complied with specific for **inhalation anesthetics and cytotoxic injectable drugs.**

5.1 For inhalation anesthetics

5.1.1 Submit **certification from the bidder that inhalation bottle must be with safety sealed cap**, airtight and capable to dispense directly from bottle the possibility of ambient air coming into contact with agent to prevent contamination and spillage.

5.1.2 Submit **certification from the bidder that product container or anesthetic agent is shatterproof and transparent for visual check of content.** Container material must ensure stability of the agent to prevent degradation, must not be easy to break.

5.1.3 Winning bidder for Sevoflurane shall *provide at least thirty-five (35) vaporizers* on loan and in good working conditions until the validity of the contract.

5.2 For Cytotoxic Injectable Drugs

5.2.1 For cytotoxic injectable drugs, winning bidders are required to *provide Material Safety Data Sheet (MSDS) and to submit Drug Profile* to the Pharmacy Department per company under the first Purchase Order.

5.2.2 Winning bidders for cytotoxic injectable drugs are required to **provide at least three (3) spill kits** per company under the first Purchase Order.

5.2.3 For Paclitaxel, a special IV set must be provided per unit of the drug.

6 **New brands offered** shall be subject to further evaluation and shall require the following:

- a. Validation of the submitted Certificate of Acceptance from at least three (3) major hospitals;

Proj. Ref. No. BAC4-21-033-A

End-User Property and Supply Division

Project SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (AMPULES/VIALS) FOR CY 2022
(FRAMEWORK AGREEMENT)

Opening of Bids: 11 January 2022

b. Justification from end-user/s to validate the acceptance of the good/s offered (to be facilitated by PGH-PSD).

7 For the supply and delivery of awarded drugs and medicines.

7.1 Delivery of the goods is required as stated in the request of the end-user, commencing on the 3rd working day of notification through confirmed fax/email that the approved Call-off/ Notice to Supplier (NTS) is already available for pick up.

7.2 Delivery schedule (whichever is applicable):

a) within seven (7) calendar days

b) as may be called for;

c) staggered delivery within three (3) months

* 50% of the total quantity within seven (7) calendar days and 25% each for the succeeding months

Note: The end-user has the right to adjust the quantity to be delivered depending on the actual need of the hospital

7.3 Deliveries shall have **at least two (2) years expiration date.**

7.4 Delivery of goods **with product complaint shall be put on hold** until receipt of the final decision of the PGH management whether to proceed with the acceptance or to cancel/return the items.

7.5 Delivered **items found to be non-formulary at any given time shall be returned** to the company and a credit memo shall be issued.

7.6 Stocks delivered **are subject to random sampling for testing** as to quality and conformity to label. Testing fee at supplier's expense.

7.7 Stocks with lot #/batch different from the submitted Certificate of Analysis (COA) will be subjected to testing as to quality and conformity to label. Testing fee at supplier's expense.

7.8 All items that had been pulled out for various reasons, a credit memo shall be issued by the Contractor within one (1) month, otherwise, a debit memo shall be processed by UP Manila - PGH and the amount will be deducted from any amount due to Supplier.

7.9 It is understood that the Supplier is legally responsible to deliver all issued **CALL-OFF/s** (Purchase Order) and **failure to deliver the first Call-Off as scheduled shall mean automatic cancellation of the Call-Off and Notice to Execute Framework Agreement (NEFA).**

Purchase from other source for whatever means shall be effected immediately to provide the requirements of the hospital. Penalty to the defaulting contractor shall be charged accordingly.

8 Failure to comply with the submission of the required documents shall be ground for post-disqualification in accordance with RA 9184.

9 Compliance with RA 9184 and other applicable laws.

University of the Philippines Manila

The Health Sciences Center

BIDS & AWARDS COMMITTEE IV (BAC IV)

Proj. Ref. No. BAC4-21-033-A

End-User Property and Supply Division

Project SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES (AMPULES/VIALS) FOR CY 2022
(FRAMEWORK AGREEMENT)

Opening of Bids: 11 January 2022



Dean VICENTE Y. BELIZARIO, JR., M.D.

Chairperson

(Signature over Printed Name of President/Gen. Manager)

(Name & Address of Company)